Welcome to our dedicated page for ORGANON & CO news (Ticker: OGN), a resource for investors and traders seeking the latest updates and insights on ORGANON & CO stock.
News about Organon & Co. (NYSE: OGN) centers on its activities as a global healthcare company focused on Women’s Health, General Medicines and biosimilars. Company press releases repeatedly describe a portfolio of over 70 products and a mission to deliver impactful medicines and solutions for a healthier every day, with particular emphasis on health needs that uniquely, disproportionately or differently affect women.
Visitors to this news page will find updates on Organon’s product and portfolio developments, including regulatory milestones, commercialization agreements and clinical data presentations. Recent announcements feature US Food and Drug Administration approvals of biosimilars such as BILDYOS and BILPREVDA for all indications of their reference products, and POHERDY as an interchangeable biosimilar to PERJETA for HER2-positive breast cancer. Organon also reports European Commission approvals for BILDYOS and BILPREVDA, expanding access to bone health treatments across the EU.
Organon’s news flow also covers women’s health and dermatology data, such as Phase 3 ADORING program results for VTAMA cream in children with atopic dermatitis, and agreements like the planned divestiture of the JADA System to Laborie and the commercialization of Nilemdo in selected European markets. Financial and corporate governance updates appear through quarterly earnings releases, capital allocation decisions, leadership changes and disclosures related to the Audit Committee investigation into Nexplanon wholesaler sales practices.
For investors, analysts and healthcare observers, the Organon news stream provides insight into how the company manages its women’s health, biosimilars and established brands portfolios, responds to regulatory developments and adjusts its leadership and balance sheet. Regularly reviewing these updates can help readers follow Organon’s evolving product mix, geographic reach and governance actions over time.
Organon (NYSE: OGN) has filed its Form 10-Q for Q1 2021, detailing financial results as a Merck spinoff. The financial statements abide by GAAP but do not represent the company's standalone financial condition. The company reaffirms its 2021 guidance, expecting revenue between $6.1 billion and $6.4 billion and an Adjusted EBITDA margin of 36.0% to 38.0%. Organon will report Q2 results on August 12, 2021, alongside its first standalone earnings call. The company focuses on women's health with a robust portfolio and aims to leverage growth opportunities globally.
Organon (NYSE: OGN) has successfully completed its acquisition of Alydia Health, a medical device company dedicated to preventing maternal morbidity and mortality due to postpartum hemorrhage (PPH). The acquisition, valued at $240 million, strengthens Organon's commitment to addressing women's healthcare needs. Alydia's Jada® System, which promotes uterine contraction to reduce excessive bleeding post-childbirth, received FDA marketing authorization in 2020. This strategic move expands Organon's portfolio into the medical device sector, enhancing its presence in reproductive health.
Organon (NYSE: OGN) celebrates its launch as a global women's health company with an opening bell ceremony at the NYSE. The company focuses on addressing women's health needs, emphasizing reproductive health and unique health issues. Organon's portfolio includes over 60 products across 140 markets, generating approximately $6.5 billion annually, with 80% from outside the U.S. Key growth areas include Women’s Health, Biosimilars, and Established Brands. The firm aims to enhance women's health through innovation and has a majority female board to guide its mission.